インクレチンベース医薬品の世界市場レポート2025年

インクレチンベース医薬品市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR7.2%で367億米ドルに成長します。予測期間中に予想される成長は、合剤療法の採用の増加、体重管理と肥満に伴う糖尿病への重点的な取り組みの増加、個別化医療とコンパニオン診断の進歩、低侵襲ドラッグデリバリー法に対する需要の高まり、合併症の負担が大きい高齢化などに起因すると考えられます。予測期間中に予測される主な動向には、肥満治療プログラムへのインクレチン製剤の組み込み、代謝転帰を改善するためのデュアルアゴニストおよびトリプルアゴニストの出現、個別化モニタリングのためのインクレチン療法とデジタルヘルスツールの統合、高度な糖尿病管理のための単剤療法よりも併用療法の優位性、投与頻度を減らすための長時間作用型週1回注射への注目の高まりなどがあります。

2型糖尿病の有病率の増加は、今後数年間のインクレチンベース医薬品市場の成長を牽引すると予想されます。2型糖尿病は、インスリン抵抗性とインスリン分泌の低下により血糖値が上昇する慢性代謝疾患です。この病態は、主に食生活の乱れや運動不足などの要因によって引き起こされ、これらの要因がインスリン抵抗性を助長し、血糖を調節する身体の能力を損ないます。インクレチンベース医薬品は、食後のインスリン分泌を促進し、グルカゴンの産生を減少させることによって血糖値を下げ、2型糖尿病の管理に役立ちます。また、胃排出を遅らせ、食欲を抑制することで、より良いグルコースコントロールと体重減少をサポートします。例えば、2024年6月、英国の政府機関である国民保健サービス（National Health Service）は、2023年にはイングランドで新たに約54万9000人が2型糖尿病を発症するリスクがあり、糖尿病予備軍の総数は360万人以上に増加すると報告しました。したがって、2型糖尿病の有病率の上昇がインクレチンベース医薬品市場の成長を促進しています。

インクレチンベース医薬品市場の主要企業は、2型糖尿病のより効果的で患者に優しい治療法を提供するため、ジェネリック医薬品の開発に注力しています。ジェネリック医薬品は、先発医薬品と同じ有効成分、強さ、剤形、投与経路を含むが、ブランド名を付けずに化学名で販売されます。例えば、2024年12月、英国に本社を置く製薬会社ヒクマ・ファーマシューティカルズPLCは、米国で最初のビクトーザ（リラグルチド）注射剤6mg/mLのジェネリック医薬品を発売しました。本剤は、10歳以上の成人および小児の2型糖尿病患者を対象に、食事療法および運動療法の補助として血糖コントロールを改善する治療薬であり、GLP-1製剤の供給不足が続く中、より安価な治療選択肢を提供するものです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のインクレチンベース医薬品：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のインクレチンベース医薬品市場：成長率分析
• 世界のインクレチンベース医薬品市場の実績：規模と成長, 2019-2024
• 世界のインクレチンベース医薬品市場の予測：規模と成長, 2024-2029, 2034F
• 世界のインクレチンベース医薬品：総潜在市場規模（TAM）

第6章 市場セグメンテーション

• 世界のインクレチンベース医薬品市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• グルカゴン様ペプチド-1受容体（GLP-1）作動薬
• ジペプチジルペプチダーゼ-4（DPP-4）阻害剤
• 世界のインクレチンベース医薬品市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 注射剤
• 世界のインクレチンベース医薬品市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界のインクレチンベース医薬品市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 2型糖尿病
• 肥満
• その他の用途
• 世界のインクレチンベース医薬品市場グルカゴン様ペプチド-1受容体（GLP-1）作動薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• エキセナチド
• リラグルチド
• デュラグルチド
• セマグルチド
• リキシセナチド
• アルビグルチド
• 世界のインクレチンベース医薬品市場ジペプチジルペプチダーゼ-4（DPP-4）阻害剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• シタグリプチン
• サグリプチン
• リナグリプチン
• アログリプチン
• ビルダグリプチン

第7章 地域別・国別分析

• 世界のインクレチンベース医薬品市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のインクレチンベース医薬品市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• インクレチンベース医薬品市場：競合情勢
• インクレチンベース医薬品市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• AstraZeneca PLC
• Novartis AG
• GlaxoSmithKline plc
• Eli Lilly and Company
• Takeda Pharmaceutical Company Limited
• Amgen Inc.
• Novo Nordisk A/S
• Viatris
• Boehringer Ingelheim GmbH
• Astellas Pharma Inc.
• Daiichi Sankyo Company Limited
• Sun Pharmaceutical Industries Ltd.
• Sumitomo Dainippon Pharma Co. Ltd.
• Hikma Pharmaceuticals PLC
• Lupin Limited

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• インクレチンベース医薬品市場2029：新たな機会を提供する国
• インクレチンベース医薬品市場2029：新たな機会を提供するセグメント
• インクレチンベース医薬品市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Incretin-based drugs are medications used to manage type 2 diabetes by enhancing the effects of incretin hormones, which stimulate insulin release after meals. These drugs aid in controlling blood sugar levels, suppressing appetite, and supporting weight loss. They also help prevent sharp increases in blood glucose and generally have a low risk of causing severe hypoglycemia.

The primary types of incretin-based drugs include glucagon-like peptide-1 receptor (GLP-1) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. GLP-1 receptor agonists imitate the natural GLP-1 hormone to boost insulin secretion, reduce glucagon levels, delay gastric emptying, and lower blood sugar in individuals with type 2 diabetes and obesity. These drugs are administered via different routes, such as oral and injectable forms, and are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies, for applications such as type 2 diabetes, obesity, and other related conditions.

The incretin-based drugs market research report is one of a series of new reports from The Business Research Company that provides incretin-based drugs market statistics, including the incretin-based drugs industry global market size, regional shares, competitors with the incretin-based drugs market share, detailed incretin-based drugs market segments, market trends, opportunities, and any further data you may need to thrive in the incretin-based drugs industry. This incretin-based drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The incretin-based drugs market size has grown strongly in recent years. It will grow from $25.89 billion in 2024 to $27.83 billion in 2025 at a compound annual growth rate (CAGR) of 7.5%. The growth during the historic period can be attributed to the increasing global prevalence of type 2 diabetes, the launch of GLP-1 receptor agonists such as exenatide and liraglutide, substantial investments in research and development, favorable regulatory approvals for DPP-4 and GLP-1 medications, a transition from insulin and sulfonylureas to newer drug classes, and the introduction of once-weekly injectable formulations.

The incretin-based drugs market size is expected to see strong growth in the next few years. It will grow to $36.70 billion in 2029 at a compound annual growth rate (CAGR) of 7.2%. The growth expected in the forecast period can be attributed to the rising adoption of fixed-dose combination therapies, increased emphasis on weight management and diabetes associated with obesity, advancements in personalized medicine and companion diagnostics, growing demand for minimally invasive drug delivery methods, and an aging population with a higher burden of comorbidities. Key trends projected for the forecast period include the incorporation of incretin drugs into obesity treatment programs, the emergence of dual and triple agonists to improve metabolic outcomes, the integration of digital health tools with incretin therapies for personalized monitoring, the predominance of combination therapies over monotherapies for advanced diabetes management, and a growing focus on long-acting weekly injections to reduce dosing frequency.

The increasing prevalence of type 2 diabetes mellitus is expected to drive the growth of the incretin-based drugs market in the coming years. Type 2 diabetes mellitus is a chronic metabolic condition marked by insulin resistance and reduced insulin secretion, resulting in elevated blood glucose levels. This condition is primarily caused by factors such as poor diet and physical inactivity, which contribute to insulin resistance and impair the body's ability to regulate blood sugar. Incretin-based drugs help manage type 2 diabetes by enhancing insulin secretion after meals and decreasing glucagon production, thereby lowering blood sugar levels. They also slow gastric emptying and suppress appetite, supporting better glucose control and weight reduction. For example, in June 2024, the National Health Service, a UK-based government organization, reported that in 2023 approximately 549,000 additional individuals in England were at risk of developing type 2 diabetes, increasing the total number of people with pre-diabetes to over 3.6 million-a rise of nearly 20% from 2022. Hence, the rising prevalence of type 2 diabetes mellitus is fueling the growth of the incretin-based drugs market.

Leading companies in the incretin-based drugs market are concentrating on developing generic drug versions to provide more effective and patient-friendly treatment options for type 2 diabetes. A generic drug contains the same active ingredients, strength, dosage form, and route of administration as its brand-name counterpart but is marketed under its chemical name without branding. For example, in December 2024, Hikma Pharmaceuticals PLC, a pharmaceutical company based in the UK, launched the first generic version of Victoza (liraglutide) injection, 6 mg/mL, in the United States. The drug received approval from the Food and Drug Administration (FDA) and is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes, offering a more affordable treatment option amid ongoing shortages of GLP-1 medications.

In July 2024, Roche, a pharmaceutical company headquartered in Switzerland, acquired Carmot Therapeutics for approximately $2.7 billion. This strategic acquisition is aimed at enhancing Roche's presence in the rapidly expanding obesity and metabolic disease market by incorporating Carmot's innovative injectable and oral therapies into its pharmaceuticals division. Carmot Therapeutics is a U.S.-based clinical-stage biotechnology company specializing in obesity and diabetes, with a strong focus on incretin-based therapies, including GLP-1 and GIP receptor agonists.

Major players in the incretin-based drugs market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Amgen Inc., Novo Nordisk A/S, Viatris, Boehringer Ingelheim GmbH, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Sumitomo Dainippon Pharma Co. Ltd., Hikma Pharmaceuticals PLC, Lupin Limited, Mitsubishi Tanabe Pharma Corporation.

North America was the largest region in the incretin-based drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in incretin-based drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the incretin-based drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The incretin-based drugs market consists of sales of dual or multi-agonists, glucagon receptor co-agonists, and fixed-dose combination drugs. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the drugs, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the drugs.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Incretin-Based Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on incretin-based drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for incretin-based drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The incretin-based drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Glucagon-Like Peptide-1 Receptor (GLP-1) Agonists; Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
• 2) By Route Of Administration: Oral; Injectable
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 4) By Application: Type 2 Diabetes; Obesity; Other Applications
• Subsegments:
• 1) By Glucagon-Like Peptide-1 Receptor (GLP-1) Agonists: Exenatide; Liraglutide; Dulaglutide; Semaglutide; Lixisenatide; Albiglutide
• 2) By Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: Sitagliptin; Saxagliptin; Linagliptin; Alogliptin; Vildagliptin
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Roche Holding AG; AbbVie Inc.; Bristol-Myers Squibb Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Incretin-Based Drugs Market Characteristics

3. Incretin-Based Drugs Market Trends And Strategies

4. Incretin-Based Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Incretin-Based Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Incretin-Based Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Incretin-Based Drugs Market Growth Rate Analysis
• 5.4. Global Incretin-Based Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Incretin-Based Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Incretin-Based Drugs Total Addressable Market (TAM)

6. Incretin-Based Drugs Market Segmentation

• 6.1. Global Incretin-Based Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Glucagon-Like Peptide-1 Receptor (GLP-1) Agonists
• Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
• 6.2. Global Incretin-Based Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectable
• 6.3. Global Incretin-Based Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.4. Global Incretin-Based Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Type 2 Diabetes
• Obesity
• Other Applications
• 6.5. Global Incretin-Based Drugs Market, Sub-Segmentation Of Glucagon-Like Peptide-1 Receptor (GLP-1) Agonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Exenatide
• Liraglutide
• Dulaglutide
• Semaglutide
• Lixisenatide
• Albiglutide
• 6.6. Global Incretin-Based Drugs Market, Sub-Segmentation Of Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Sitagliptin
• Saxagliptin
• Linagliptin
• Alogliptin
• Vildagliptin

7. Incretin-Based Drugs Market Regional And Country Analysis

• 7.1. Global Incretin-Based Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Incretin-Based Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Incretin-Based Drugs Market

• 8.1. Asia-Pacific Incretin-Based Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Incretin-Based Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Incretin-Based Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Incretin-Based Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Incretin-Based Drugs Market

• 9.1. China Incretin-Based Drugs Market Overview
• 9.2. China Incretin-Based Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Incretin-Based Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Incretin-Based Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Incretin-Based Drugs Market

• 10.1. India Incretin-Based Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Incretin-Based Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Incretin-Based Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Incretin-Based Drugs Market

• 11.1. Japan Incretin-Based Drugs Market Overview
• 11.2. Japan Incretin-Based Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Incretin-Based Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Incretin-Based Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Incretin-Based Drugs Market

• 12.1. Australia Incretin-Based Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Incretin-Based Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Incretin-Based Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Incretin-Based Drugs Market

• 13.1. Indonesia Incretin-Based Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Incretin-Based Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Incretin-Based Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Incretin-Based Drugs Market

• 14.1. South Korea Incretin-Based Drugs Market Overview
• 14.2. South Korea Incretin-Based Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Incretin-Based Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Incretin-Based Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Incretin-Based Drugs Market

• 15.1. Western Europe Incretin-Based Drugs Market Overview
• 15.2. Western Europe Incretin-Based Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Incretin-Based Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Incretin-Based Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Incretin-Based Drugs Market

• 16.1. UK Incretin-Based Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Incretin-Based Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Incretin-Based Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Incretin-Based Drugs Market

• 17.1. Germany Incretin-Based Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Incretin-Based Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Incretin-Based Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Incretin-Based Drugs Market

• 18.1. France Incretin-Based Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Incretin-Based Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Incretin-Based Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Incretin-Based Drugs Market

• 19.1. Italy Incretin-Based Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Incretin-Based Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Incretin-Based Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Incretin-Based Drugs Market

• 20.1. Spain Incretin-Based Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Incretin-Based Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Incretin-Based Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Incretin-Based Drugs Market

• 21.1. Eastern Europe Incretin-Based Drugs Market Overview
• 21.2. Eastern Europe Incretin-Based Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Incretin-Based Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Incretin-Based Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Incretin-Based Drugs Market

• 22.1. Russia Incretin-Based Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Incretin-Based Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Incretin-Based Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Incretin-Based Drugs Market

• 23.1. North America Incretin-Based Drugs Market Overview
• 23.2. North America Incretin-Based Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Incretin-Based Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Incretin-Based Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Incretin-Based Drugs Market

• 24.1. USA Incretin-Based Drugs Market Overview
• 24.2. USA Incretin-Based Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Incretin-Based Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Incretin-Based Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Incretin-Based Drugs Market

• 25.1. Canada Incretin-Based Drugs Market Overview
• 25.2. Canada Incretin-Based Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Incretin-Based Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Incretin-Based Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Incretin-Based Drugs Market

• 26.1. South America Incretin-Based Drugs Market Overview
• 26.2. South America Incretin-Based Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Incretin-Based Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Incretin-Based Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Incretin-Based Drugs Market

• 27.1. Brazil Incretin-Based Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Incretin-Based Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Incretin-Based Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Incretin-Based Drugs Market

• 28.1. Middle East Incretin-Based Drugs Market Overview
• 28.2. Middle East Incretin-Based Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Incretin-Based Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Incretin-Based Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Incretin-Based Drugs Market

• 29.1. Africa Incretin-Based Drugs Market Overview
• 29.2. Africa Incretin-Based Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Incretin-Based Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Incretin-Based Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Incretin-Based Drugs Market Competitive Landscape And Company Profiles

• 30.1. Incretin-Based Drugs Market Competitive Landscape
• 30.2. Incretin-Based Drugs Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. Incretin-Based Drugs Market Other Major And Innovative Companies

• 31.1. AstraZeneca PLC
• 31.2. Novartis AG
• 31.3. GlaxoSmithKline plc
• 31.4. Eli Lilly and Company
• 31.5. Takeda Pharmaceutical Company Limited
• 31.6. Amgen Inc.
• 31.7. Novo Nordisk A/S
• 31.8. Viatris
• 31.9. Boehringer Ingelheim GmbH
• 31.10. Astellas Pharma Inc.
• 31.11. Daiichi Sankyo Company Limited
• 31.12. Sun Pharmaceutical Industries Ltd.
• 31.13. Sumitomo Dainippon Pharma Co. Ltd.
• 31.14. Hikma Pharmaceuticals PLC
• 31.15. Lupin Limited

32. Global Incretin-Based Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Incretin-Based Drugs Market

34. Recent Developments In The Incretin-Based Drugs Market

35. Incretin-Based Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Incretin-Based Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Incretin-Based Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Incretin-Based Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer